Wikisage, the free encyclopedia of the second generation, is digital heritage
Fabry disease: Difference between revisions
Jump to navigation
Jump to search
(categ) |
No edit summary |
||
| Line 9: | Line 9: | ||
*improves diarrhea | *improves diarrhea | ||
https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0813-7 | https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0813-7 | ||
[https://www.ncbi.nlm.nih.gov/pubmed/30064518 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY] | [https://www.ncbi.nlm.nih.gov/pubmed/30064518 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY] | ||
Latest revision as of 03:21, 11 August 2018
Fabry disease is a genetic condition involving lysosomal storage [1]is an X-linked disorder caused by alpha-galactosidase A deficiency [2]
Disease classification WHO
Fabry disease E75.2
migalastat or 1-deoxygalactonojirimycin received an orphan drug approval [3]
- improves diarrhea
https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0813-7
Anderson-Fabry disease in heart failure
Galafold [summary of product characteristics]. Buckinghamshire, UK; Amicus Therapeutics UK Ltd: 2017